CD8A and cancer: Epitope-based vaccines that are made of B- or T-cell epitopes have been reported to elicit strong immune responses (12–13,19,25); CTLs (CD8+ T cells or killer T cells) kill cancer cells and also kill target cells infected with intracellular viruses, bacteria or protozoa (53).